These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33174213)

  • 1. The other possible mechanism of the benefits of RAAS inhibition in the athogenesis of COVID-19.
    Gupta N; Patel K; Gupta R
    Clin Cardiol; 2020 Dec; 43(12):1349. PubMed ID: 33174213
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 and the Renin-Angiotensin-Aldosterone System.
    Naik GOA
    Clin Infect Dis; 2021 Mar; 72(6):1105-1107. PubMed ID: 32561913
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessment of ACE inhibitors/angiotensin receptor blockers in COVID-19 patients.
    Sriram K; Insel PA
    Am J Physiol Lung Cell Mol Physiol; 2020 Jul; 319(1):L37-L38. PubMed ID: 33496632
    [No Abstract]   [Full Text] [Related]  

  • 4. Do the Meta-Analyses Provide a Clean Bill of Health to the Use of Renin-angiotensin System Inhibitors in Coronavirus Disease 2019 (COVID-19)?
    Kow CS; Hasan SS
    Clin Infect Dis; 2021 Jul; 73(1):164-165. PubMed ID: 32770237
    [No Abstract]   [Full Text] [Related]  

  • 5. Potential Roles of the Renin-Angiotensin System in the Pathogenesis and Treatment of COVID-19.
    Lu L; Liu X; Jin R; Guan R; Lin R; Qu Z
    Biomed Res Int; 2020; 2020():7520746. PubMed ID: 33204713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From Foe to Friend in COVID-19: Renin-Angiotensin System Inhibitors.
    Kidde J; Sahebkar A
    J Infect Dis; 2021 Jan; 223(1):174-175. PubMed ID: 33010158
    [No Abstract]   [Full Text] [Related]  

  • 7. Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and COVID-19: Demonstrating the Actionability of Real-World Evidence.
    Hennessy S; Cohen JB
    Am J Hypertens; 2021 Apr; 34(4):327-329. PubMed ID: 33156920
    [No Abstract]   [Full Text] [Related]  

  • 8. Is there a difference in the effect between the ACEI and ARB on COVID-19?
    Chen J; Mei K; Deng C
    Clin Cardiol; 2021 Jan; 44(1):5-6. PubMed ID: 33205837
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to "How Important Is the Assessment of Soluble ACE-2 in COVID-19?".
    Rieder M; Bode C; Duerschmied D; Lother A
    Am J Hypertens; 2021 Apr; 34(3):298. PubMed ID: 33201224
    [No Abstract]   [Full Text] [Related]  

  • 10. RAAS inhibitors in COVID-19: They are not all the same!
    Kow CS; Ramachandram DS; Hasan SS
    Rev Port Cardiol; 2023 Sep; 42(9):815-816. PubMed ID: 37353197
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to: RAAS inhibitors in COVID-19: Not all are created equal!
    Gonçalves J; Santos CD; Fresco P; Fernandez-Llimos F
    Rev Port Cardiol; 2023 Sep; 42(9):817-818. PubMed ID: 37356667
    [No Abstract]   [Full Text] [Related]  

  • 12. Did our pharmacological strategy for COVID-19 fail?
    Martin JH; Baddeley M; Head R
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00866. PubMed ID: 34708568
    [No Abstract]   [Full Text] [Related]  

  • 13. Renin-angiotensin system inhibitors in hospitalised patients with COVID-19.
    Williams B
    Lancet Respir Med; 2021 Mar; 9(3):221-222. PubMed ID: 33422264
    [No Abstract]   [Full Text] [Related]  

  • 14. Elevated baseline renin levels as a possible cause of worse prognosis of COVID-19 in patients with heart disease.
    Guerrero Pérez E; Andreu Cayuelas JM; Navarro Peñalver M; Mateo Martínez A
    Rev Esp Cardiol (Engl Ed); 2021 Feb; 74(2):203-204. PubMed ID: 33309674
    [No Abstract]   [Full Text] [Related]  

  • 15. On the imbalanced protective arm of RAS in COVID-19: Lesson from rare genetic tubulopathies.
    Davis PA; Bertoldi G; Calò LA
    Int J Clin Pract; 2021 May; 75(5):e14075. PubMed ID: 33887873
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical Impact Potential of Supplemental Nutrients as Adjuncts of Therapy in High-Risk COVID-19 for Obese Patients.
    Sahin E; Orhan C; Uckun FM; Sahin K
    Front Nutr; 2020; 7():580504. PubMed ID: 33195370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review.
    Kaye AG; Siegel R
    PeerJ; 2020; 8():e10322. PubMed ID: 33194450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Causal inference methods for small non-randomized studies: Methods and an application in COVID-19.
    Friedrich S; Friede T
    Contemp Clin Trials; 2020 Dec; 99():106213. PubMed ID: 33188930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Back to basics: review on vitamin D and respiratory viral infections including COVID-19.
    Balla M; Merugu GP; Konala VM; Sangani V; Kondakindi H; Pokal M; Gayam V; Adapa S; Naramala S; Malayala SV
    J Community Hosp Intern Med Perspect; 2020 Oct; 10(6):529-536. PubMed ID: 33194123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial aspects of high dose intravenous vitamin C on patients with COVID-19 pneumonia in severe condition: a retrospective case series study.
    Zhao B; Ling Y; Li J; Peng Y; Huang J; Wang Y; Qu H; Gao Y; Li Y; Hu B; Lu S; Lu H; Zhang W; Mao E
    Ann Palliat Med; 2021 Feb; 10(2):1599-1609. PubMed ID: 33222462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.